About Teleflex Inc
- Industry: Health Care
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.teleflex.com/usa/en/#
Frequently Asked Questions
What is the 52-week range for TFX?
The 52-week high is $145 and the 52-week low is $100.18.
What is the P/E ratio for TFX?
The P/E ratio data is currently unavailable.
What is the dividend yield for TFX?
The indicated annual dividend yield is 0.62%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -31.90%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -39.67%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.73.
Analyst Recommendation Trends
Wall Street analyst consensus for TFX over the last few months:
Latest TFX News
3 Healthcare Stocks That Concern Us
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 37% over the past six months, topping the S&P 500 by 20.7 percentage points.
Boston Scientific's MedSurg Diversification Bolsters Growth Prospects
BSX's MedSurg segment supports growth, with Endoscopy and Neuromodulation gains offsetting Urology challenges and portfolio gaps.
This Nice Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday
Wall Street analysts upgraded Grocery Outlet, NICE and Pinnacle Financial Partners; targets are $15, $150 and $118, respectively.
Stocks making big moves yesterday: TTM Technologies, PacBio, Nvidia, Palo Alto Networks, and Teleflex
Check out the companies making headlines yesterday:
This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Analysts upgraded STAA, NFLX, SFIX, with ratings moving toward Buy or Neutral and mixed price-target changes.
Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology
WAYNE, Pa., September 29, 2026--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology were associated with a statistically significant 70% lower hazard of central line-associated bloodstream infections (CLABSIs) compared with plain, non-impregnated catheters during a
Teleflex (TFX) Soars 4.4%: Is Further Upside Left in the Stock?
Teleflex (TFX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Should New Leadership And Debt Focus At Teleflex (TFX) Require Action From Investors?
Recently, Teleflex attracted attention as investors reacted to commentary that, despite weak constant-currency revenue growth and declining earnings metrics, some see the company as lagging broader market performance while others highlight its potential. What stands out is that new leadership and an emphasis on reducing debt are being framed as possible catalysts for a meaningful re-rating story in the eyes of investment firms. Next, we’ll examine how Teleflex’s new leadership focus and...
Why Teleflex (TFX) Stock Is Trading Up Today
Shares of medical technology company Teleflex (NYSE:TFX) jumped 4.5% in the afternoon session after BofA Securities upgraded the stock from Neutral to Buy and raised its price target.
Nyxoah Appoints Liam Kelly as Chief Executive Officer
REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Appoints Liam Kelly as Chief Executive Officer Further strengthening the Company’s strategic U.S. presence and focus Mont-Saint-Guibert, Belgium – September 28, 2026, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of Liam Kelly as
3 Reasons to Avoid TFX and 1 Stock to Buy Instead
Even though Teleflex (currently trading at $122.08 per share) has gained 6.2% over the last six months, it has lagged the S&P 500’s 21.4% return during that period. This may have investors wondering how to approach the situation.
Teleflex Growth Prospects, New Leadership Could Drive 2027 Re-Rating, BofA Securities Says
Teleflex (TFX) could be the next re-rating story, with its growth prospects, new leadership and pote
First Solar upgraded, Celsius downgraded: Wall Street's top analyst calls
First Solar upgraded, Celsius downgraded: Wall Street's top analyst calls
Nasdaq 100 Sinks, Oil Rallies as Trump Rejects Iran's Hormuz Plan: Stock Market Today
Stocks slipped at midday Monday as oil surged and yields hit a 19-year high after Trump rejected Iran's Hormuz plan; MongoDB tumbled 18%.
Here Are Monday’s Top Wall Street Analyst Research Calls: Applied Digital, Autodesk, Datadog, First Solar, L3Harris Technologies, PepsiCo, Roblox, Snowflake, TeraWulf and More
Pre-Market Stock Futures: Futures are trading lower as we enter the final trading days of the third quarter, after a wild week in which interest rates soared and oil prices bounced back and forth. While all major indices closed higher on Friday, only two finished the week higher, and with the quarter ending, watch for […]
This First Solar Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Analysts upgraded Royal Caribbean, Park Hotels, First Solar, Teleflex and CF Industries, with several receiving higher price targets.
B of A Securities Upgrades Teleflex to Buy, Raises Price Target to $158
B of A Securities analyst Craig Bijou upgrades Teleflex (NYSE:TFX) from Neutral to Buy and raises the price target from $145 to $158.
Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now
QGEN's test menu expansion and strategic partnerships support growth, but cautious spending and competition may weigh on near-term gains.
Illumina Stock Surges 94.9% YTD: What's Behind the Rally?
ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.
Should You Continue to Hold IDXX Stock in Your Portfolio?
IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.
Is This the Right Time to Add DGX Stock to Your Portfolio?
Quest Diagnostics gains momentum from customer wins, advanced diagnostics and AI initiatives, while reimbursement uncertainty, costs and debt pose challenges.
Teleflex (TFX) Adds A Board Veteran, Is The 19% Undervalued View Enough?
Teleflex board refresh puts governance in focus Teleflex (TFX) has added veteran medical device executive Sean M. Salmon to its Board of Directors. This appointment gives investors a fresh angle on the company’s governance and its long term direction. Teleflex shares have eased in the short term, with the 7 day share price return down 4.94% and the 30 day share price return down 10.31%. The 90 day share price return of 2.34% and 1 year total shareholder return of 2.67% point to only modest...
IDEXX Stock Gains Following the Acquisition of CoVet
IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
PEN's portfolio expansion and international growth support momentum, while rising costs, FX exposure and margin pressure remain key risks.
Should Investors Add EYE Stock to Their Portfolios Now?
National Vision's premium-product demand and stronger customer mix support growth, but rising costs and vendor dependence remain key risks for investors.
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.
5 Low P/B Stocks That Offer Attractive Value and Growth
TFX, CNC, ENS, ROCK and FAF stand out among five low P/B stocks offering attractive value and promising growth prospects.
Should You Continue to Hold ALGN Stock in Your Portfolio?
Align Technology expands Invisalign and digital dentistry adoption as iTero gains traction, but weak capital spending and currency volatility remain risks.
TFX vs. PEN: Which Stock Is the Better Value Option?
TFX vs. PEN: Which Stock Is the Better Value Option?
Is This the Right Time to Add Neogen Stock to Your Portfolio?
NEOG advances product innovation and recovers Animal Safety operations, but high debt and intense competition remain key risks.
Surgical Equipment & Consumables - Specialty Stocks Q2 Earnings Review: Teleflex (NYSE:TFX) Shines
Looking back on surgical equipment & consumables - specialty stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Teleflex (NYSE:TFX) and its peers.
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
WAYNE, Pa., September 08, 2026--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026.
Should You Continue to Hold TMO Stock in Your Portfolio?
Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.
Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026
WAYNE, Pa., September 04, 2026--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technologies will be the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System. This technology is supported by the previously presented BIONETIC-TRA study, an investigator-initiated study with
Teleflex (TFX): Guidance Cut Meets A Bigger Buyback Push
On August 6, Teleflex Incorporated (NYSE:TFX) reported second-quarter results for the period ended June 30, and the numbers told two different stories at once. Revenue from continuing operations climbed to $570.3 million, up 28.9% from a year earlier, while GAAP diluted earnings per share slid to $0.96 from $1.54. Add in a completed divestiture, a […]
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-08 | Salmon Sean | +4,444 | - | - |
| 2026-09-08 | Salmon Sean | +674 | - | - |
| 2026-06-08 | Weidman Jason R. | +26,071 | - | - |
| 2026-06-08 | Weidman Jason R. | +53,983 | - | - |
| 2026-06-08 | RANDLE STUART A | +2,192 | - | - |
| 2026-06-08 | RANDLE STUART A | +4,663 | - | - |
| 2026-06-08 | RANDLE STUART A | +995 | - | - |
| 2026-06-07 | RANDLE STUART A | -4,054 | $129.84 | $526,371 |
| 2026-05-15 | Ryu Jaewon | +2,397 | - | - |
| 2026-05-15 | Ryu Jaewon | +1,090 | - | - |
| 2026-05-15 | Patil Neena M | +2,397 | - | - |
| 2026-05-15 | Patil Neena M | +1,090 | - | - |
| 2026-05-15 | Duncan Candace H | +2,397 | - | - |
| 2026-05-15 | Duncan Candace H | +1,090 | - | - |
| 2026-05-15 | Krakauer Andrew A | +2,397 | - | - |
| 2026-05-15 | Krakauer Andrew A | +1,090 | - | - |
| 2026-05-15 | HAGGERTY GRETCHEN R | +2,397 | - | - |
| 2026-05-15 | HAGGERTY GRETCHEN R | +1,090 | - | - |
| 2026-05-15 | TOKICH MICHAEL J | +4,793 | - | - |
| 2026-05-15 | TOKICH MICHAEL J | +1,090 | - | - |
| 2026-05-09 | RANDLE STUART A | -289 | $133.06 | $38,454 |
| 2026-03-04 | Logue Daniel V. | -131 | $119.18 | $15,613 |
| 2026-03-04 | Winters James | -247 | $119.18 | $29,437 |
| 2026-03-04 | Deren John | -229 | $119.18 | $27,292 |
| 2026-03-04 | Hicks Cameron P | -98 | $119.18 | $11,680 |
| 2026-03-03 | Logue Daniel V. | +21,510 | - | - |
| 2026-03-03 | Logue Daniel V. | +6,591 | - | - |
| 2026-03-03 | Logue Daniel V. | +3,262 | - | - |
| 2026-03-03 | Winters James | +21,510 | - | - |
| 2026-03-03 | Winters James | +9,745 | - | - |
| 2026-03-03 | Winters James | +3,262 | - | - |
| 2026-03-03 | Deren John | +30,362 | - | - |
| 2026-03-03 | Deren John | +9,180 | - | - |
| 2026-03-03 | Deren John | +4,604 | - | - |
| 2026-03-03 | Hicks Cameron P | +16,133 | - | - |
| 2026-03-03 | Hicks Cameron P | +5,649 | - | - |
| 2026-03-03 | Hicks Cameron P | +2,447 | - | - |
| 2026-02-28 | Logue Daniel V. | -484 | $122.06 | $59,077 |
| 2026-02-28 | Winters James | -661 | $122.06 | $80,682 |
| 2026-02-28 | Hicks Cameron P | -396 | $122.06 | $48,336 |
| 2026-02-28 | Deren John | -231 | $122.06 | $28,196 |
| 2026-02-23 | Logue Daniel V. | +443 | - | - |
| 2026-02-23 | Winters James | +354 | - | - |
| 2026-02-23 | Deren John | +161 | - | - |
| 2026-02-23 | Hicks Cameron P | +352 | - | - |
| 2026-01-13 | RANDLE STUART A | +12,325 | - | - |